• Athira Pharma to Participate in Upcoming May Conferences

    Source: Nasdaq GlobeNewswire / 02 May 2024 06:00:00   America/Chicago

    BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May.

    Sidoti May 2024 Virtual Investor Conference
    Format: Company Presentation
    Date and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET
    Location: Virtual

    The Citizens JMP Life Sciences Conference
    Format: Fireside Chat
    Date and Time: Monday, May 13, 2024, from 1:30 p.m. - 1:55 p.m. ET
    Location: New York Hilton Midtown

    Live webcasts of the panel and presentations can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor. An archived replay of the webcasts will be available for at least 30 days following the event.

    About Athira Pharma, Inc.
    Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton, which is being evaluated for the potential treatment of mild-to-moderate Alzheimer’s disease in the Phase 2/3 LIFT-AD trial that is expected to report topline data in the second half of 2024. For more information, visit www.athira.com. You can also follow Athira on FacebookLinkedIn and @athirapharma on X, (formerly known as Twitter), and Instagram.

    Investor Contacts:
    Julie Rathbun
    Athira Pharma
    Julie.rathbun@athira.com
    206-769-9219

    Anne Marie Fields
    Stern Investor Relations
    annemarie.fields@sternir.com
    332-213-1956

    Media Contact:
    Janine Bogris
    Inizio Evoke Comms
    Janine.bogris@inizioevoke.com
    201-245-6838


    Primary Logo

Share on,